...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International clinical psychopharmacology >Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: A randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder
【24h】

Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: A randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder

机译：伏替西汀（Lu AA21004）的疗效和安全性（每天15毫克和20毫克）：一项随机，双盲，安慰剂对照，度洛西汀为参考的研究，用于成人严重抑郁症的急性治疗

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

This study assessed the efficacy, tolerability and safety of vortioxetine versus placebo in adults with recurrent major depressive disorder. This double-blind, randomized, placebo-controlled study included 608 patients [Montgomery-?sberg Depression Rating Scale (MADRS) total score≥26 and Clinical Global Impression-Severity score≥4]. Patients were randomly assigned (1 : 1 : 1 : 1) to vortioxetine 15 mg/day, vortioxetine 20 mg/day, duloxetine 60 mg/day or placebo. The primary efficacy endpoint was change from baseline in MADRS total score at week 8 (mixed model for repeated measurements). Key secondary endpoints were: MADRS responders; Clinical Global Impression- Improvement scale score; MADRS total score in patients with baseline Hamilton Anxiety Rating Scale ≥20; remission (MADRS≤10); and Sheehan Disability Scale total score at week 8. On the primary efficacy endpoint, both vortioxetine doses were statistically significantly superior to placebo, with a mean difference to placebo (n=158) of-5.5 (vortioxetine 15 mg, P<0.0001, n=149) and-7.1 MADRS points (vortioxetine 20 mg, P<0.0001, n=151). Duloxetine (n=146) separated from placebo, thus validating the study. In all key secondary analyses, both vortioxetine doses were statistically significantly superior to placebo. Vortioxetine treatment was well tolerated; common adverse events (incidence≥5%) were nausea, headache, diarrhea, dry mouth and dizziness. No clinically relevant changes were seen in clinical safety laboratory values, weight, ECG or vital signs parameters. Vortioxetine was efficacious and well tolerated in the treatment of patients with major depressive disorder.
机译：这项研究评估了伏立西汀与安慰剂在复发性重度抑郁症成人中的疗效，耐受性和安全性。这项双盲，随机，安慰剂对照研究包括608例患者[蒙哥马利抑郁量表（MADRS）总分≥26，临床总体印象严重度得分≥4]。患者被随机分配（1：1 1：1 1：1）伏替西汀15 mg /天，伏替西汀20 mg /天，度洛西汀60 mg /天或安慰剂。主要功效终点是第8周时MADRS总评分的基线变化（重复测量的混合模型）。主要的次要终点是：MADRS响应者;临床总体印象-改善量表评分;基线汉密尔顿焦虑量表≥20的患者的MADRS总分;缓解（MADRS≤10）;和Sheehan Disability Scale第8周的总评分。在主要疗效终点，两种伏替西汀剂量在统计学上均显着优于安慰剂，与安慰剂的平均差异（n = 158）为-5.5（伏替西汀15 mg，P <0.0001，n = 149）和-7.1 MADRS点（伏替西汀20 mg，P <0.0001，n = 151）。度洛西汀（n = 146）从安慰剂中分离出来，从而验证了该研究。在所有关键的次要分析中，伏立西汀的两种剂量在统计学上均显着优于安慰剂。伏替西汀治疗耐受性良好;常见不良事件（发生率≥5％）为恶心，头痛，腹泻，口干和头晕。在临床安全实验室值，体重，ECG或生命体征参数方面未见临床相关变化。伏替西汀在重度抑郁症患者的治疗中有效且耐受良好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号